Insider Buying: OncoCyte Co. (NASDAQ:OCX) Director Acquires $26,375.00 in Stock

OncoCyte Co. (NASDAQ:OCX) Director Andrew Arno bought 12,500 shares of OncoCyte stock in a transaction dated Thursday, December 26th. The shares were bought at an average cost of $2.11 per share, for a total transaction of $26,375.00. Following the completion of the transaction, the director now owns 81,554 shares of the company’s stock, valued at approximately $172,078.94. This trade represents a 18.10 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

OncoCyte Stock Performance

NASDAQ:OCX opened at $2.11 on Friday. The firm has a 50-day simple moving average of $2.62 and a 200-day simple moving average of $2.90. OncoCyte Co. has a one year low of $1.97 and a one year high of $3.82.

OncoCyte (NASDAQ:OCX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.54). The business had revenue of $0.12 million during the quarter. OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. During the same period last year, the business earned ($0.57) earnings per share. On average, research analysts forecast that OncoCyte Co. will post -2.57 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on OCX shares. Needham & Company LLC reissued a “buy” rating and issued a $4.25 price objective on shares of OncoCyte in a research note on Wednesday, November 13th. StockNews.com began coverage on OncoCyte in a research report on Thursday. They set a “sell” rating on the stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in OncoCyte stock. Geode Capital Management LLC raised its stake in OncoCyte Co. (NASDAQ:OCX) by 12.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 103,980 shares of the company’s stock after purchasing an additional 11,289 shares during the period. Geode Capital Management LLC owned 0.62% of OncoCyte worth $296,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 55.35% of the company’s stock.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.